These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38987116)

  • 1. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial.
    Li H; Aggarwal A; Toro P; Fu P; Badve SS; Cuzick J; Madabhushi A; Thorat MA
    Lancet Digit Health; 2024 Aug; 6(8):e562-e569. PubMed ID: 38987116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
    Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
    Clin Cancer Res; 2021 Oct; 27(19):5317-5324. PubMed ID: 34380636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Schiza A; Thurfjell V; Stenmark Tullberg A; Olofsson H; Lindberg A; Holmberg E; Bremer T; Micke P; Karlsson P; Wärnberg F; Strell C
    Eur J Cancer; 2022 Jun; 168():128-137. PubMed ID: 35236568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
    Solin LJ; Gray R; Baehner FL; Butler SM; Hughes LL; Yoshizawa C; Cherbavaz DB; Shak S; Page DL; Sledge GW; Davidson NE; Ingle JN; Perez EA; Wood WC; Sparano JA; Badve S
    J Natl Cancer Inst; 2013 May; 105(10):701-10. PubMed ID: 23641039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
    Miligy I; Mohan P; Gaber A; Aleskandarany MA; Nolan CC; Diez-Rodriguez M; Mukherjee A; Chapman C; Ellis IO; Green AR; Rakha EA
    Histopathology; 2017 Aug; 71(2):258-268. PubMed ID: 28326600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
    Strell C; Folkvaljon D; Holmberg E; Schiza A; Thurfjell V; Karlsson P; Bergh J; Bremer T; Akslen LA; Wärnberg F; Östman A
    Clin Cancer Res; 2021 Jun; 27(12):3469-3477. PubMed ID: 33952629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma
    Thorat MA; Levey PM; Jones JL; Pinder SE; Bundred NJ; Fentiman IS; Cuzick J
    Clin Cancer Res; 2021 May; 27(10):2861-2867. PubMed ID: 33727261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
    Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
    Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
    Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
    Solin LJ; Gray R; Hughes LL; Wood WC; Lowen MA; Badve SS; Baehner FL; Ingle JN; Perez EA; Recht A; Sparano JA; Davidson NE
    J Clin Oncol; 2015 Nov; 33(33):3938-44. PubMed ID: 26371148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.
    Lazzeroni M; DeCensi A; Guerrieri-Gonzaga A; Pagan E; Bagnardi V; Macis D; Serrano D; Vingiani A; Bonizzi G; Barberis M; Pruneri G; Wagner S; Gandini S; Viale G; Bonanni B
    Mod Pathol; 2020 Jun; 33(6):1065-1077. PubMed ID: 31925342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.
    Wright JL; Gray R; Rahbar H; Comstock CE; Tjoe JA; Badve S; Recht A; Sparano JA; Davidson NE; Wolff AC
    NPJ Breast Cancer; 2024 Feb; 10(1):16. PubMed ID: 38396024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
    Guerini-Rocco E; Bellerba F; Concardi A; Taormina SV; Cammarata G; Fumagalli C; Guerrieri-Gonzaga A; Macis D; Del Fiol Manna E; Balladore E; Cannone M; Veronesi P; Fusco N; Bonanni B; Viale G; Barberis M; Gandini S; Lazzeroni M
    Eur J Cancer; 2024 May; 203():114063. PubMed ID: 38615592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels.
    Yang L; Lu D; Lai Y; Shen M; Yu Q; Lei T; Pu T; Bu H
    Ann Surg Oncol; 2021 Feb; 28(2):975-984. PubMed ID: 32794031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Biological Signature for Breast Ductal Carcinoma
    Bremer T; Whitworth PW; Patel R; Savala J; Barry T; Lyle S; Leesman G; Linke SP; Jirström K; Zhou W; Amini RM; Wärnberg F
    Clin Cancer Res; 2018 Dec; 24(23):5895-5901. PubMed ID: 30054280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay.
    Lei RY; Carter DL; Antell AG; Nowels MA; Tole SP; Bennett JP; Turner M; Baehner FL; Leonard CE
    Adv Radiat Oncol; 2021; 6(2):100607. PubMed ID: 33912731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.